{"filing":{"accession_number":"0001159036-26-000103","cik":"0001159036","ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"halo-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000103/halo-20260806.htm"},"events":[{"id":25461,"run_id":23112,"accession_number":"0001159036-26-000103","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Halozyme issued a press release on August 6, 2026, reporting financial results for Q2 2026 ended June 30, 2026, disclosing total revenue of $481 million (48% YOY growth), royalty revenue of $308 million (50% YOY growth), and raising full-year 2026 financial guidance across multiple metrics including total revenue, royalty revenue, adjusted EBITDA, and non-GAAP diluted EPS. This is a standard quarterly earnings release furnished under Item 2.02.","company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26298,"accession_number":"0001159036-26-000103","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Halozyme issued a press release on August 6, 2026, reporting financial results for Q2 2026 ended June 30, 2026, disclosing total revenue of $481 million (48% YOY growth), royalty revenue of $308 million (50% YOY growth), and raising full-year 2026 financial guidance across multiple metrics including total revenue, royalty revenue, adjusted EBITDA, and non-GAAP diluted EPS. This is a standard quarterly earnings release furnished under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:46:52.229662+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26298,"accession_number":"0001159036-26-000103","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Halozyme issued a press release on August 6, 2026, reporting financial results for Q2 2026 ended June 30, 2026, disclosing total revenue of $481 million (48% YOY growth), royalty revenue of $308 million (50% YOY growth), and raising full-year 2026 financial guidance across multiple metrics including total revenue, royalty revenue, adjusted EBITDA, and non-GAAP diluted EPS. This is a standard quarterly earnings release furnished under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:46:52.229662+00:00","company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","filing_date":"2026-08-06"}]}